Literature DB >> 29712652

First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae.

Dhruvitkumar S Sutaria1, Bartolome Moya1, Kari B Green2, Tae Hwan Kim1, Xun Tao1, Yuanyuan Jiao1, Arnold Louie3, George L Drusano3, Jürgen B Bulitta4.   

Abstract

Penicillin-binding proteins (PBPs) are the high-affinity target sites of all β-lactam antibiotics in bacteria. It is well known that each β-lactam covalently binds to and thereby inactivates different PBPs with various affinities. Despite β-lactams serving as the cornerstone of our therapeutic armamentarium against Klebsiella pneumoniae, PBP binding data are missing for this pathogen. We aimed to generate the first PBP binding data on 13 chemically diverse and clinically relevant β-lactams and β-lactamase inhibitors in K. pneumoniae PBP binding was determined using isolated membrane fractions from K. pneumoniae strains ATCC 43816 and ATCC 13883. Binding reactions were conducted using β-lactam concentrations from 0.0075 to 256 mg/liter (or 128 mg/liter). After β-lactam exposure, unbound PBPs were labeled by Bocillin FL. Binding affinities (50% inhibitory concentrations [IC50]) were reported as the β-lactam concentrations that half-maximally inhibited Bocillin FL binding. PBP occupancy patterns by β-lactams were consistent across both strains. Carbapenems bound to all PBPs, with PBP2 and PBP4 as the highest-affinity targets (IC50, <0.0075 mg/liter). Preferential PBP2 binding was observed by mecillinam (amdinocillin; IC50, <0.0075 mg/liter) and avibactam (IC50, 2 mg/liter). Aztreonam showed high affinity for PBP3 (IC50, 0.06 to 0.12 mg/liter). Ceftazidime bound PBP3 at low concentrations (IC50, 0.06 to 0.25 mg/liter) and PBP1a/b at higher concentrations (4 mg/liter), whereas cefepime bound PBPs 1 to 4 at more even concentrations (IC50, 0.015 to 2 mg/liter). These PBP binding data on a comprehensive set of 13 clinically relevant β-lactams and β-lactamase inhibitors in K. pneumoniae enable, for the first time, the rational design and optimization of double β-lactam and β-lactam-β-lactamase inhibitor combinations.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  BLIs; Enterobacteriaceae; Klebsiella pneumoniae; PBPs; beta-lactamase inhibitors; beta-lactams; drug-resistant bacteria; occupancy patterns; penicillin-binding proteins; pharmacodynamics; principal component analysis; receptor binding

Mesh:

Substances:

Year:  2018        PMID: 29712652      PMCID: PMC5971569          DOI: 10.1128/AAC.00282-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

2.  Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.

Authors:  Bartolomé Moyá; Laura Zamorano; Carlos Juan; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients.

Authors:  D J Winston; W G Ho; D A Bruckner; R P Gale; R E Champlin
Journal:  Am J Med       Date:  1988-07-25       Impact factor: 4.965

4.  Characterization of the extended-spectrum beta-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18.

Authors:  J K Rasheed; G J Anderson; H Yigit; A M Queenan; A Doménech-Sánchez; J M Swenson; J W Biddle; M J Ferraro; G A Jacoby; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.

Authors:  Akihiro Morinaka; Yuko Tsutsumi; Mototsugu Yamada; Kenji Suzuki; Takashi Watanabe; Takao Abe; Takeshi Furuuchi; Seiichi Inamura; Yoshiaki Sakamaki; Nakako Mitsuhashi; Takashi Ida; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2015-06-18       Impact factor: 5.790

6.  Ticarcillin in combination with cephalothin or gentamicin as empiric antibiotic therapy in granulocytopenic cancer patients.

Authors:  S C Schimpff; S Landesman; D M Hahn; H C Standiford; C L Fortner; V M Young; P H Wiernik
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

Review 7.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

8.  Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.

Authors:  D J Winston; R C Barnes; W G Ho; L S Young; R E Champlin; R P Gale
Journal:  Am J Med       Date:  1984-09       Impact factor: 4.965

Review 9.  Amdinocillin: a novel penicillin. Antibacterial activity, pharmacology and clinical use.

Authors:  H C Neu
Journal:  Pharmacotherapy       Date:  1985 Jan-Feb       Impact factor: 4.705

Review 10.  The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis.

Authors:  Eric Sauvage; Frédéric Kerff; Mohammed Terrak; Juan A Ayala; Paulette Charlier
Journal:  FEMS Microbiol Rev       Date:  2008-02-11       Impact factor: 16.408

View more
  15 in total

1.  Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.

Authors:  Yuanyuan Jiao; Bartolome Moya; Mong-Jen Chen; Alexandre P Zavascki; Hsinyin Tsai; Xun Tao; Dhruvitkumar S Sutaria; Arnold Louie; John D Boyce; Deanna Deveson Lucas; Tae Hwan Kim; Brian T Tsuji; Robert A Bonomo; George L Drusano; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.

Authors:  Bartolome Moya; Isabel M Barcelo; Gabriel Cabot; Gabriel Torrens; Snehal Palwe; Prashant Joshi; Kushal Umarkar; Swapna Takalkar; Hariharan Periasamy; Sachin Bhagwat; Mahesh Patel; German Bou; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.

Authors:  T A Alsenani; S L Viviani; V Kumar; M A Taracila; C R Bethel; M D Barnes; K M Papp-Wallace; R K Shields; M H Nguyen; C J Clancy; R A Bonomo; F van den Akker
Journal:  Antimicrob Agents Chemother       Date:  2022-03-28       Impact factor: 5.938

Review 4.  β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates.

Authors:  Montserrat Mora-Ochomogo; Christopher T Lohans
Journal:  RSC Med Chem       Date:  2021-08-04

5.  Comparison of Bioorthogonal β-Lactone Activity-Based Probes for Selective Labeling of Penicillin-Binding Proteins.

Authors:  Nathaniel W Brown; Joshua D Shirley; Andrew P Marshall; Erin E Carlson
Journal:  Chembiochem       Date:  2020-11-16       Impact factor: 3.164

6.  Slt, MltD, and MltG of Pseudomonas aeruginosa as Targets of Bulgecin A in Potentiation of β-Lactam Antibiotics.

Authors:  David A Dik; Chinedu S Madukoma; Shusuke Tomoshige; Choonkeun Kim; Elena Lastochkin; William C Boggess; Jed F Fisher; Joshua D Shrout; Shahriar Mobashery
Journal:  ACS Chem Biol       Date:  2019-01-18       Impact factor: 5.100

Review 7.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

8.  Semimechanistic Pharmacodynamic Modeling of Aztreonam-Avibactam Combination to Understand Its Antimicrobial Activity Against Multidrug-Resistant Gram-Negative Bacteria.

Authors:  Alexia Chauzy; Bruna Gaelzer Silva Torres; Julien Buyck; Boudewijn de Jonge; Christophe Adier; Sandrine Marchand; William Couet; Nicolas Grégoire
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-08-16

9.  First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.

Authors:  Alaa R M Sayed; Nirav R Shah; Kari B Basso; Manasi Kamat; Yuanyuan Jiao; Bartolome Moya; Dhruvitkumar S Sutaria; Yinzhi Lang; Xun Tao; Weiguo Liu; Eunjeong Shin; Jieqiang Zhou; Carolin Werkman; Arnold Louie; George L Drusano; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.938

10.  Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae.

Authors:  Tae Hwan Kim; Xun Tao; Bartolome Moya; Yuanyuan Jiao; Kari B Basso; Jieqiang Zhou; Yinzhi Lang; Dhruvitkumar S Sutaria; Alexandre P Zavascki; Afonso L Barth; Stephanie M Reeve; Herbert P Schweizer; Deanna Deveson Lucas; John D Boyce; Robert A Bonomo; Richard E Lee; Beom Soo Shin; Arnold Louie; George L Drusano; Jürgen B Bulitta
Journal:  mBio       Date:  2020-02-11       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.